Bausch Health: FDA Accepts NDA For IDP-123 Lotion for Acne
07 August 2019 - 10:23PM
Dow Jones News
By Colin Kellaher
Bausch Health Cos. (BHC, BHC.T) on Wednesday said the U.S. Food
and Drug Administration accepted a new-drug application for its
Ortho Dermatologics unit's IDP-123 lotion for acne vulgaris, the
most common skin problem in the U.S.
The Laval, Quebec, maker of pharmaceutical products said
IDP-123, if approved, would be the first tazarotene acne treatment
available in a lotion form.
Bausch said the FDA has set a target action date of Dec. 22 for
the NDA.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2019 08:08 ET (12:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From Apr 2024 to May 2024
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From May 2023 to May 2024